Early clinical case studies

With extensive medical and operational experience, we deliver seamless execution in both healthy volunteer and patient cohort studies, providing critical safety and tolerability data in the early clinical stages of development.

Delivering high quality data in a complex heart failure trial

CardioResearch and ICON partnered to deliver a complex phase 1b–2a heart failure trial through collaborative expertise, governance, and innovative operational execution.

Solving complexity in early clinical imaging

ICON partnered with the University Medical Center Groningen to deliver a complex crossover study with 240 brain MRIs in 60 participants, delivering fast, consistent data and a seamless experience.

ADME and ABA trial in solid tumor patients

This phase 1 oncology ADME and ABA study faced strict eligibility, screening, radiolabeled drug logistics, and 72-hour shelf-life constraints, requiring precise coordination, specialised expertise and patient recruitment.

Recruitment success in a challenging phase 1 osteoporosis biosimilar study

Successful 3-arm, double-blind study on a denosumab biosimilar in 225 healthy men over 10 months at two ICON sites.

Global coordination for phase 1 success

A pharma client partnered with ICON to support EU and US approval of a new diabetes therapy. ICON’s APS team sourced, labeled, and shipped comparator and study drugs for a complex phase 1 trial, helping meet the sponsor’s accelerated timeline.

Overcoming enrollment challenges in an early phase obesity trial

A large pharma company partnered with ICON to conduct a phase 1 obesity study assessing the safety and tolerability of a new investigational oral amycretin therapy.

Complex phase 1 obesity study

ICON was once again selected as a partner to conduct a phase 1 study in individuals who are overweight or have obesity, evaluating the safety and tolerability of a new subcutaneous GLP-1 and amylin peptide formulation.

Early phase study for non-opioid pain treatment

A leading biotech company developing a groundbreaking non-opioid treatment for moderate-to-severe acute pain partnered with ICON to conduct a series of early phase trials.

Accelerated auxiliary medicine procurement for MASH trial

ICON's Accelerated Pharmaceuticals Solutions sourced, labeled, and globally distributed vitamin D for a phase 3 study, preventing delays and improving supply chain agility.

Rapid IV formulation development for FIH ADME study

Analytical method development, validation, stability testing and compatibility assessments for a large pharma sponsor.

Multinational phase 1 biosimilar study

ICON conducted a multinational biosimilar phase 1 study for multiple sclerosis (MS). This trial was performed under high regulatory scrutiny and challenging pandemic conditions, with increased dosing targets requiring additional site activation.